Summary & Overview
HCPCS J2930: Methylprednisolone Injection, Up to 125 mg
HCPCS Level II code J2930 designates a single administration of methylprednisolone sodium succinate, up to 125 mg, a commonly used parenteral corticosteroid for acute inflammatory and allergic conditions. Nationally, this code matters because it standardizes billing for an injectable medication frequently used across outpatient and ambulatory settings, influencing payer coverage determinations and facility billing workflows. Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for use of methylprednisolone injections, common sites of service where J2930 is billed, and the typical billing considerations associated with this HCPCS Level II code. The publication also summarizes benchmark topics such as reimbursement framing for ambulatory injectable medications, common modifier usage patterns (listed separately), and policy updates impacting injectable drug billing. Data limitations: Data not available in the input for associated taxonomies, ICD-10 diagnoses, related codes, and payer-specific rates. The content is intended for national audiences seeking a concise reference on clinical purpose and billing context for J2930.
Billing Code Overview
HCPCS Level II code J2930 represents the administration of methylprednisolone sodium succinate injection, up to 125 mg. This entry describes the billed supply for a single injectable corticosteroid dose formulation used to manage inflammatory and allergic conditions.
-
Service Type: Injection
-
Typical Site of Service: Ambulatory clinics, physician offices, outpatient infusion centers, and other outpatient settings where parenteral medications are administered.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 56-year-old adult presenting to an ambulatory clinic or emergency department with acute exacerbation of inflammatory or painful musculoskeletal conditions such as an acute flare of osteoarthritis, bursitis, tendonitis, or an acute gout flare that has not responded to oral therapy. After clinical evaluation and review of contraindications (active systemic infection, poorly controlled diabetes without benefit-risk discussion), the clinician selects intramuscular or intraarticular administration of methylprednisolone sodium succinate to reduce inflammation and pain. The procedure is performed in an outpatient clinic, physician office, urgent care, or ambulatory surgery center. The workflow includes informed consent, medication preparation (up to 125 mg of methylprednisolone sodium succinate billed as J2930), site antisepsis, local anesthesia if indicated, administration of the steroid by syringe or injection device, observation for immediate adverse reaction, and documentation of drug name, dose, lot number, route, site, and any modifier that explains unusual circumstances (for example, active monitoring or bilateral procedure). Typical post-procedure instructions and follow-up scheduling are provided before discharge to home.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Office or other outpatient visit | When the global period does not apply and an evaluation/management service is reported with the injection in the office. |